Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Lori Anne Kunkel sold 10,000 shares of the business’s stock in a transaction on Monday, July 6th. The stock was sold at an average price of $50.49, for a total value of $504,900.00. Following the completion of the transaction, the director directly owned 41,884 shares of the company’s stock, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Lori Anne Kunkel also recently made the following trade(s):
- On Friday, June 5th, Lori Anne Kunkel sold 10,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $34.54, for a total value of $345,400.00.
Enliven Therapeutics Stock Performance
Enliven Therapeutics stock traded down $0.12 during midday trading on Wednesday, reaching $50.80. 1,117,930 shares of the company were exchanged, compared to its average volume of 1,337,794. The firm’s 50-day simple moving average is $42.83 and its 200-day simple moving average is $34.13. Enliven Therapeutics, Inc. has a 1 year low of $14.78 and a 1 year high of $52.39. The company has a market capitalization of $3.09 billion, a price-to-earnings ratio of -30.42 and a beta of 0.24.
Analyst Ratings Changes
Several equities analysts recently issued reports on ELVN shares. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Guggenheim assumed coverage on shares of Enliven Therapeutics in a research note on Tuesday, May 12th. They issued a “buy” rating and a $80.00 target price for the company. Mizuho increased their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research note on Tuesday, June 2nd. Weiss Ratings restated a “sell (d-)” rating on shares of Enliven Therapeutics in a report on Monday, April 20th. Finally, The Goldman Sachs Group lifted their price objective on Enliven Therapeutics from $41.00 to $59.00 and gave the company a “buy” rating in a research report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $67.83.
Institutional Inflows and Outflows
Several large investors have recently modified their holdings of the stock. FNY Investment Advisers LLC acquired a new stake in shares of Enliven Therapeutics in the second quarter worth approximately $126,000. Assenagon Asset Management S.A. purchased a new stake in Enliven Therapeutics in the second quarter valued at approximately $15,559,000. Seven Fleet Capital Management LP increased its position in Enliven Therapeutics by 159.4% during the first quarter. Seven Fleet Capital Management LP now owns 259,283 shares of the company’s stock worth $10,164,000 after purchasing an additional 159,330 shares during the last quarter. DV Trading LLC acquired a new position in Enliven Therapeutics during the first quarter worth approximately $3,734,000. Finally, Avidity Partners Management LP raised its stake in Enliven Therapeutics by 185.1% during the first quarter. Avidity Partners Management LP now owns 400,000 shares of the company’s stock worth $15,680,000 after purchasing an additional 259,700 shares during the period. 95.08% of the stock is currently owned by hedge funds and other institutional investors.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.
The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.
Featured Stories
- Five stocks we like better than Enliven Therapeutics
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Enliven Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enliven Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
